Video

Significance of Analyzing Gene Mutations in Prostate Cancer

Author(s):

Joshua Armenia, PhD

In Partnership With:

Joshua Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the significance of analyzing mutated genes in prostate cancer.

Joshua Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the significance of analyzing mutated genes in prostate cancer.

The biggest cohort of patients with prostate cancer has not led to the discovery of biomarkers for advanced disease. Primary metastatic tumors need to be studied in more detail to determine the evolution of this disease.

It would also be interesting to identify markers of progression for patients with advanced disease within primary tumors by comparing the genomic alterations across lesions.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Related Content
Alison Schram, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center
January 2nd 2025

FDA Approval Insights: Zenocutuzumab for NRG1+ Pancreatic Adenocarcinoma and NSCLC: With Alison Schram, MD

James J. Harding, MD, director, Early Drug Development, Memorial Sloan Kettering Cancer Center
December 30th 2024

FDA Approval Insights: Zanidatamab in Pretreated, HER2+ Biliary Tract Cancer

Carol Aghajanian, MD, of Memorial Sloan Kettering Cancer Center
December 28th 2024

Shaking Up Gynecologic Cancer Treatment With Mentorship and Patient-Centric Care

Komal Jhaveri, MD, FACP, section head, Endocrine Therapy Research Program, clinical director, Early Drug Development Service, Patricia and James Cayne Chair for Junior Faculty, Memorial Sloan Kettering Cancer Center
August 22nd 2024

Jhaveri on the INAVO120 Trial of Inavolisib/Palbociclib/Fulvestrant in PIK3CA -Mutant, HR+ Breast Cancer

Breast cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
December 11th 2024

Imlunestrant With or Without Abemaciclib Boosts PFS in ESR1+, ER+/HER2– Advanced Breast Cancer

Prostate Cancer
December 11th 2024

CAN-2409 Improves DFS in Intermediate/High-Risk Localized Prostate Cancer